Aligos Therapeutics, Inc. (ALGS) Stock

Aligos Therapeutics, Inc. (ALGS) is a Healthcare stock trading at $5.30 (as of 2026-06-18), with a market capitalization of $41.84M and a trailing P/E of -2.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for viral and liver diseases, including chronic hepatitis B. Its pipeline includes ALG-010133 and ALG-000184, along with additional hepatitis B–targeting candidates and programs in non-alcoholic steatohepatitis and other approaches.

Valuation — source: SEC EDGAR (first-party)
Price	$5.30
Market Cap	$41.84M
P/E Ratio	-2.1
EV / EBITDA	-0.0
Price / Book	1.03
Price / Sales	6.94
DCF Value (model)	$-224.36
DCF Upside vs Price	-4329.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.19M
Net Margin	-1106.7%
Return on Equity	-284.1%
Current Ratio	2.56
Revenue Growth (YoY)	-39.5%
EPS Growth (YoY)	-88.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-12.01 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-109.9%
vs Industry	-112.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Deep Track Capital, LP ($3.30M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Lawrence Blatt
Employees	70
Country	US
IPO Date	2020-10-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.